CL2022002808A1 - Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas - Google Patents

Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas

Info

Publication number
CL2022002808A1
CL2022002808A1 CL2022002808A CL2022002808A CL2022002808A1 CL 2022002808 A1 CL2022002808 A1 CL 2022002808A1 CL 2022002808 A CL2022002808 A CL 2022002808A CL 2022002808 A CL2022002808 A CL 2022002808A CL 2022002808 A1 CL2022002808 A1 CL 2022002808A1
Authority
CL
Chile
Prior art keywords
subject
kif18a
tumor
methods
neoplastic disease
Prior art date
Application number
CL2022002808A
Other languages
English (en)
Inventor
Noel Payton Marc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2022002808A1 publication Critical patent/CL2022002808A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

En el presente documento se proporcionan métodos para tratar a un sujeto que tiene una enfermedad neoplásica, que comprenden administrar al sujeto un inhibidor de KIF18A en una cantidad eficaz para tratar la enfermedad neoplásica y una enfermedad neoplásica en un sujeto. También se proporcionan métodos para inducir o aumentar la regresión tumoral en un sujeto con un tumor y métodos para reducir el crecimiento tumoral o del cáncer en un sujeto. En aspectos de ejemplo, el método comprende administrar al sujeto un inhibidor de KIF18A. En el presente documento también se proporcionan métodos para inducir o aumentar la muerte de células tumorales o cancerosas en un sujeto que comprenden administrar al sujeto un inhibidor de KIF18A. Ventajosamente, los inhibidores de KIF18A tratan selectivamente la enfermedad neoplásica, inducen o aumentan la regresión tumoral y/o inducen o aumentan la muerte de células tumorales o cancerosas sin una toxicidad manifiesta para las células somáticas normales.
CL2022002808A 2020-04-14 2022-10-12 Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas CL2022002808A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009637P 2020-04-14 2020-04-14
US202063055111P 2020-07-22 2020-07-22
US202063085607P 2020-09-30 2020-09-30

Publications (1)

Publication Number Publication Date
CL2022002808A1 true CL2022002808A1 (es) 2023-05-26

Family

ID=75660432

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002808A CL2022002808A1 (es) 2020-04-14 2022-10-12 Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas

Country Status (13)

Country Link
US (1) US20230151432A1 (es)
EP (1) EP4136263A1 (es)
JP (1) JP2023521802A (es)
KR (1) KR20230011932A (es)
CN (1) CN115667551A (es)
AU (1) AU2021257801A1 (es)
BR (1) BR112022020817A2 (es)
CA (1) CA3177740A1 (es)
CL (1) CL2022002808A1 (es)
IL (1) IL297242A (es)
MX (1) MX2022012992A (es)
TW (1) TW202203919A (es)
WO (1) WO2021211549A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202321213A (zh) * 2021-07-21 2023-06-01 美商安進公司 Ｋｉｆ１８ａ抑制劑化合物之鹽和固態形式
WO2023088441A1 (zh) * 2021-11-19 2023-05-25 微境生物医药科技(上海)有限公司 Kif18a抑制剂
WO2023146973A1 (en) * 2022-01-26 2023-08-03 Amgen Inc. Synthesis of a kif18a inhibitor
WO2023174175A1 (zh) * 2022-03-17 2023-09-21 微境生物医药科技(上海)有限公司 Kif18a抑制剂
WO2023212714A1 (en) 2022-04-29 2023-11-02 Amgen Inc. Kif18a inhibition for treatment of cancer
WO2024002328A1 (zh) * 2022-06-30 2024-01-04 勤浩医药（苏州）有限公司 一种含氮化合物及其应用
CN117466899A (zh) * 2022-07-29 2024-01-30 武汉人福创新药物研发中心有限公司 Kif18a抑制剂及用途
WO2024051812A1 (zh) * 2022-09-09 2024-03-14 先声再明医药有限公司 酰胺类化合物、其组合物及用途
WO2024078569A1 (zh) * 2022-10-13 2024-04-18 浙江海正药业股份有限公司 芳香酰胺类衍生物及其制备方法和用途
CN117917405A (zh) * 2022-10-21 2024-04-23 杭州邦顺制药有限公司 Kif18a蛋白抑制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
EP2314691A3 (en) * 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
US7423018B2 (en) * 2002-12-13 2008-09-09 University Of Massachusetts Kinesin-like proteins and methods of use
EP2295543A1 (en) * 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
JP2017517520A (ja) * 2014-05-29 2017-06-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｗｅｅ１阻害剤を用いた癌を処置する方法
GB201709840D0 (en) * 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
CR20210387A (es) * 2018-12-20 2021-08-19 Amgen Inc Inhibidores de kif18a
US20220372018A1 (en) * 2019-08-02 2022-11-24 Amgen Inc. Kif18a inhibitors
WO2021026098A1 (en) * 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CA3147451A1 (en) * 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors

Also Published As

Publication number Publication date
TW202203919A (zh) 2022-02-01
MX2022012992A (es) 2022-11-08
US20230151432A1 (en) 2023-05-18
KR20230011932A (ko) 2023-01-25
JP2023521802A (ja) 2023-05-25
CN115667551A (zh) 2023-01-31
EP4136263A1 (en) 2023-02-22
AU2021257801A1 (en) 2022-10-27
WO2021211549A1 (en) 2021-10-21
IL297242A (en) 2022-12-01
BR112022020817A2 (pt) 2023-03-07
CA3177740A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
CL2022002808A1 (es) Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas
CL2021001575A1 (es) Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1)
MX2020009773A (es) Terapia de combinacion.
ECSP17072756A (es) Terapia de combinación del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte programada 1 (pd-1) para el tratamiento del cáncer.
UY38263A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
AR023400A1 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
ES2422605T3 (es) Anticuerpo contra klotho-beta para utilizar en el tratamiento de tumores, cáncer o trastornos proliferativos celulares
PE20211961A1 (es) Terapia de combinacion de radioinmunoconjugados con inhibidores de danos y reparaciones del adn
CL2021002533A1 (es) Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras
MX2020001727A (es) Terapia de combinacion.
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CO2021015130A2 (es) Péptidos bnip3 para el tratamiento de la lesión por reperfusión
AR118585A1 (es) Métodos para tratar la hipertensión portopulmonar
CL2023000857A1 (es) Inhibidores line-1 para tratar la enfermedad
DOP2023000155A (es) Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina
CO2023017973A2 (es) Trampas de ligando del factor de crecimiento transformante βeta para el tratamiento de enfermedades
AR121832A1 (es) Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas
CL2020002637A1 (es) Métodos de tratamiento de cáncer.
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
CL2021001172A1 (es) Uso de tivozanib para tratar sujetos con cáncer refractario.
MX2021001764A (es) Terapia de combinacion.
PE20220250A1 (es) Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
DOP2014000221A (es) Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek